BPC-157
also known as BPC 157, BPC157, Body Protection Compound, PL-14736
Synthetic 15-amino-acid pentadecapeptide derived from a protective sequence found in human gastric juice (BPC = Body Protection Compound). Stable in simulated gastric conditions and the most extensively studied healing peptide in animal literature. Demonstrates tendon, ligament, muscle, and gastrointestinal mucosa healing across 20+ rodent models. Clinically evaluated under designation PL-14736 in a Phase 2 ulcerative colitis trial.
At a glance
SQ or IM · Local · Once or twice daily
Mechanism
Primary target — VEGFR2 / nitric oxide / FAK-paxillin axes (proposed) [chang-2014][sikiric-2018].
Pathway — Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillin [chang-2014].
Downstream effect — Accelerated tissue repair, reduced inflammation, improved gut barrier integrity [sikiric-2018].
Origin — Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al. [sikiric-2018].
Feedback intact — No known endogenous receptor; mechanism still under investigation.
Dosage
Protocols described in the cited literature; not medical advice.
| Parameter | Value |
|---|---|
| Standard dose | 250–500 mcg / day [hwang-2016]Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day. |
| Frequency | Once or twice dailySplit dosing reported anecdotally for chronic injury. |
| Lower / starter dose | 200 mcg / dayConservative starter for new users. |
| Evidence basis | Animal-strong + Phase 2 clinical [sikiric-2018][hwang-2016] |
| Duration | 2–4 weeks (acute injury); 4–8 weeks (chronic)Anecdotal; no long-term human safety data. |
| Reconstitution | Bacteriostatic water, 1–2 mL |
| Timing | Local SQ to injury site preferred (anecdotal)Systemic SQ also used; oral bioavailability shown in animal studies. |
| Half-life | ~30 min plasma (estimated)Tissue half-life longer; mechanism may explain durable effect. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Adverse events
Severities follow the FDA / CTCAE convention.
- — Pregnancy / breastfeeding
- — Known active malignancy (theoretical VEGF concern)
- — History of cancer
- — Concurrent VEGF inhibitor therapy (theoretical)
- — Acute thrombotic events
Administration
- 01Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
- 02Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
- 03Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
- 04Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
- 05Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
Synergies
Sources
of 53 rendered claims carry a resolvable citation.
- [chang-2014]Chang 2014 — The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
J Appl Physiol, 2014 - [hwang-2016]Hwang 2016 — BPC 157 (PL 14736) — Crohn's disease phase II clinical trial
Inflamm Bowel Dis, 2016 - [sikiric-2018]Sikiric 2018 — Stable gastric pentadecapeptide BPC 157, an effective anti-inflammatory agent: a comprehensive review
Curr Pharm Des, 2018